» Articles » PMID: 22277740

Reliability and Equivalence of Alternate Forms for the Symbol Digit Modalities Test: Implications for Multiple Sclerosis Clinical Trials

Overview
Journal Mult Scler
Publisher Sage Publications
Specialty Neurology
Date 2012 Jan 27
PMID 22277740
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cognitive impairment is common in multiple sclerosis (MS), but is seldom assessed in clinical trials investigating the effects of disease-modifying therapies. The Symbol Digit Modalities Test (SDMT) is a particularly promising tool due to its sensitivity and robust correlation with brain magnetic resonance imaging (MRI) and vocational disability. Unfortunately, there are no validated alternate SDMT forms, which are needed to mitigate practice effects.

Objective: The aim of the study was to assess the reliability and equivalence of SDMT alternate forms.

Methods: Twenty-five healthy participants completed each of five alternate versions of the SDMT - the standard form, two versions from the Rao Brief Repeatable Battery, and two forms specifically designed for this study. Order effects were controlled using a Latin-square research design.

Results: All five versions of the SDMT produced mean values within 3 raw score points of one another. Three forms were very consistent, and not different by conservative statistical tests. The SDMT test-retest reliability using these forms was good to excellent, with all r values exceeding 0.80.

Conclusions: For the first time, we find good evidence that at least three alternate versions of the SDMT are of equivalent difficulty in healthy adults. The forms are reliable, and can be implemented in clinical trials emphasizing cognitive outcomes.

Citing Articles

Test-retest reliability, practice effects and estimates of change: A study on the Mindmore digital cognitive assessment tool.

Bergman I, Franke Foyen L, Gustavsson A, Van den Hurk W Scand J Psychol. 2024; 66(1):1-14.

PMID: 39072723 PMC: 11735254. DOI: 10.1111/sjop.13054.


Early Strokes Are Associated with More Global Cognitive Deficits in Adults with Sickle Cell Disease.

Couette M, Forte S, Oudin Doglioni D, Mekontso-Dessap A, Calvet D, Kuo K J Clin Med. 2023; 12(4).

PMID: 36836150 PMC: 9967394. DOI: 10.3390/jcm12041615.


Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study).

Hummert M, Stern C, Paul F, Duchow A, Bellmann-Strobl J, Ayzenberg I Mult Scler. 2023; 29(7):819-831.

PMID: 36786424 PMC: 10278388. DOI: 10.1177/13524585231151212.


Time to rethink the reported disease-modifying treatment effects on cognitive outcomes: Methods and interpretative caveats.

Labiano-Fontcuberta A, Monreal E, Benito-Leon J Front Neurol. 2022; 13:995690.

PMID: 36119690 PMC: 9474887. DOI: 10.3389/fneur.2022.995690.


Cognitive fatigability assessment test (cFAST): Development of a new instrument to assess cognitive fatigability and pilot study on its association to perceived fatigue in multiple sclerosis.

Barrios L, Amon R, Oldrati P, Hilty M, Holz C, Lutterotti A Digit Health. 2022; 8:20552076221117740.

PMID: 36046638 PMC: 9421030. DOI: 10.1177/20552076221117740.